title: Acute myeloid leukemia therapeutics: CARs in the driver's seat.
abstract: Acute myeloid leukemia remains a difficult disease to cure and novel therapeutic approaches are needed. To this end, we developed CD123 chimeric antigen receptor (CAR) redirected T cells which exhibited potent antileukemic activity. We discuss what we learned during the development of CD123 CARs and future directions for this immunotherapy.
authors: Department of Hematology and Hematopoietic Cell Transplantation; City of Hope; Duarte, CA USA.
authors: Armen
authors: A
authors: Mardiros
authors: Department of Hematology and Hematopoietic Cell Transplantation; City of Hope; Duarte, CA USA.
authors: Christine E
authors: CE
authors: Brown
authors: Department of Hematology and Hematopoietic Cell Transplantation; City of Hope; Duarte, CA USA.
authors: L Elizabeth
authors: LE
authors: Budde
authors: Department of Hematology and Hematopoietic Cell Transplantation; City of Hope; Duarte, CA USA.
authors: Xiuli
authors: X
authors: Wang
authors: Department of Hematology and Hematopoietic Cell Transplantation; City of Hope; Duarte, CA USA.
authors: Stephen J
authors: SJ
authors: Forman
keywords: AML; CD123; adoptive T cell therapy; chimeric antigen receptor; immunotherapy; leukemia